Displaying 1761 - 1780 of 2081
FTC Issues Administrative Challenge to Polypore International, Inc.'s Consummated Acquisition of Microporous Products L.P. and Other Anticompetitive Conduct
Take-Two Interactive Software, Inc.
Clinical Integration in Health Care: A Check-Up
Innovations in Health Care Delivery
Unilateral Effects Analysis and Litigation Workshop
Energy Markets in the 21st Century: Competition Policy in Perspective
FTC Issues FY 2006 FDCPA Report to Congress; Commission Approves Filing of Amended Complaint in Matter of Global Marketing Group, Inc.; FTC Approves Federal Register Notice on Recycled Oil Rule; FTC Approves Federal Register Notice on Agency Systems of
Broadband Connectivity Competition Policy
MiRealSource Settles Charges it Illegally Restrained Competition
Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.
There is a related federal proceeding and two related administrative proceedings:
FTC Charges Real Estate Groups with Anticompetitive Conduct in Limiting Consumers' Choice in Real Estate Services
FTC Finds Rambus Unlawfully Obtained Monopoly Power
Displaying 1761 - 1780 of 2081